New PET tracer could spot hidden cancers
NCT ID NCT07593209
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new radioactive imaging agent called 68Ga-DOTA-EphA2 to help see certain proteins on cancer cells during PET/CT scans. The goal is to improve how doctors detect and monitor malignant tumors. About 30 adults with suspected or confirmed cancer will receive the agent and then have a scan to see where it goes in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-DOTA-EphA2 (a radioactive imaging agent)
What this could lead to
If successful, this could provide a new way to detect and monitor certain cancers more accurately using PET/CT scans.
What could go wrong
This is a small, early-phase study focused on imaging, not treatment. The agent may not work well for all tumor types, and there is a risk of side effects from the radioactive tracer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PET
RECRUITINGShenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••